Claims
- 1. A composition for in vivo imaging of a biological material, comprising:
an imaging agent in dosage unit form, wherein the unit dose of the imaging agent comprises a sufficient amount for in vivo diagnostic imaging of a 2′-deoxy-2′-[18F]-labeled or a 3′-deoxy-3′-[18F]-labeled purine nucleoside analog for being detected in vivo; and a physiologically acceptable carrier or adjuvant.
- 2. The composition of claim 1, wherein said analog is a 2′-deoxy-2′-[18F]-fluoro-9-β-D-arabinofuranosyl purine analog or a 3′-deoxy-3′-[18F]-fluro-9-β-D-xylofuranosyl purine analog.
- 3. The composition of claim 2, wherein said 2′-deoxy-2′-[18F]-fluro-9-β-D-arabinofuranosyl purine analog is 2′-deoxy-2′-[18F]-fluoro-9-β-D-arabinofuranosyladenine.
- 4. The composition of claim 2, wherein said 3′-deoxy-3′-[18F]-fluro-9-β-D-xylofuranosyl purine analog is 3′-deoxy-3′-[18F]-fluoro-9-β-D-xylofuranosyladenine.
- 5. An in vivo method for imaging a biological material in a subject, comprising:
administering to said subject a sufficient amount of a composition comprising a 2′-deoxy-2′-[18F]-labeled or a 3′-deoxy-3′-[18F]-labeled purine nucleoside analog to provide an imageable concentration of said analog in said biological material; and detecting emissions from said radioactive fluorine of said analog, thereby forming an image of said biological material.
- 6. The method of claim 5, wherein said analog is a 2′-deoxy-2′-[18F]-fluro-9-β-D-arabinofuranosyl purine analog or a 3′-deoxy-3′-[18F]-fluro-9-β-D-xylofuranosyl purine analog.
- 7. The method of claim 6, wherein said 2′-deoxy-2′-[18F]-fluoro-9-β-D-arabinofuranosyl purine analog is 2′-deoxy-2′-[18F]-fluoro-9-β-D-arabinofuranosyladenine.
- 8. The method of claim 6, wherein said 3′-deoxy-3′-[18F]-fluoro-9-β-D-xylofuranosyl purine analog is 3′-deoxy-3′-[18F]-fluoro-9-β-D-xylofuranosyladenine.
- 9. The method of claim 7, wherein said biological material is a tumor.
- 10. The method of claim 5, wherein said biological material is an organ or tissue.
- 11. The method of claim 10 wherein said organ or tissue is myocardial tissues, vascular beds, skin, muscle, bone, bone marrow, heart, lung, liver, spleen, pancreas, stomach, brain, intestine, or kidney.
- 12. The method of claim 5, wherein said detecting is by positron emission tomography.
- 13. The method of claim 5, wherein said analog is administered intravenously or intra-arterially.
- 14. The method of claim 5, wherein said analog is administered at more than one time point.
- 15. The method of claim 5, wherein said analog is administered by infusion over a period of about five minutes or more.
- 16. The method of claim 5, wherein said composition further comprises a pharmaceutically acceptable carrier.
- 17. A method for imaging the heart in a warm-blooded subject comprising the steps of
administering a composition comprising [18F]-FXA to said subject in an amount sufficient to provide an imageable concentration of said [18F]-FXA in myocardial tissue of said subject; and detecting the radioactivity of the [18F]-FXA in said tissue, thereby forming an image of said heart.
- 18. The method of claim 17, wherein said radioactivity is measured by positron emission topography.
- 19. The method of claim 17, wherein said [18F]-FXA is administered intravenously.
- 20. The method of claim 17, further comprising the risk of vascular disease in the subject, wherein said risk is based on comparing said image to an image obtained from a normal subject.
- 21. The method of claim 20, wherein said vascular disease is selected from the group consisting of atherosclerosis, coronary artery disease (CAD), myocardial infarction (MI), ischemia, stroke, peripheral vascular diseases, and venous thromboembolism.
- 22. A method for imaging a tumor in a patient, the method comprising:
administering to a patient an composition comprising [18F]-FAA in an amount sufficient to provide an imageable concentration of said [18F]-FAA; and detecting emissions from said radioactive fluorine of said [18F]-FAA, thereby forming an image of said tumor.
- 23. The method of claim 22 wherein the detecting is by positron emission tomography.
- 24. A method of synthesizing 2′-deoxy-2′-[18F]-labeled furanosyl purines, comprising:
providing a furanosyl purine, wherein the 2′-OH group of said furanosyl purine is protected by a triflate protecting group and the 3′-OH and 5′-OH groups of said furanosyl purine are protected by an alcohol protecting group other than a triflate; preparing [18F]-tetra-N-butylammonium fluoride in situ; and combining said furanosyl purine with said [18F]-n-butylammonium fluoride.
- 25. The method of claim 23, wherein said [18F]-N-butylammonium fluoride is prepared from tetra-N-butylammonium bicarbonate and aqueous H18F.
- 26. A method of synthesizing 3′-deoxy-3′-[18F]-labeled furanosyl purines, comprising:
providing a furanosyl purine, wherein the 3′-OH group of said furanosyl purine is protected by a triflate protecting group and the 2′-OH and 5′-OH groups of said furanosyl purine are protected by an alcohol protecting group other than a triflate; preparing [18F]-tetra-N-butylammonium fluoride in situ; and combining said furanosyl purine with said [18F]-n-butylammonium fluoride.
- 27. The method of claim 23, wherein said [18F]-N-butylammonium fluoride is prepared from tetra-N-butylammonium bicarbonate and aqueous H18F.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application Ser. No. 60/465,418, filed Apr. 25, 2003, and U.S. Provisional Application Ser. No. 60/480,274, filed Jun. 20, 2003, the contents of both of which are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60465418 |
Apr 2003 |
US |
|
60480274 |
Jun 2003 |
US |